Ricky Goldwasser
Stock Analyst at Morgan Stanley
(4.12)
# 432
Out of 5,182 analysts
233
Total ratings
61.49%
Success rate
8.21%
Average return
Main Sectors:
Stocks Rated by Ricky Goldwasser
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CNC Centene | Maintains: Equal-Weight | $38 → $45 | $37.28 | +20.71% | 15 | Mar 4, 2026 | |
| DOCS Doximity | Maintains: Overweight | $65 → $49 | $21.86 | +124.15% | 12 | Feb 6, 2026 | |
| UNH UnitedHealth Group | Maintains: Overweight | $411 → $409 | $305.98 | +33.67% | 21 | Jan 23, 2026 | |
| CRL Charles River Laboratories International | Maintains: Equal-Weight | $170 → $185 | $175.07 | +5.67% | 23 | Nov 11, 2025 | |
| LH Labcorp Holdings | Maintains: Overweight | $283 → $306 | $274.72 | +11.39% | 17 | Jul 25, 2025 | |
| LFST LifeStance Health Group | Reiterates: Overweight | $10 | $6.54 | +52.91% | 8 | Apr 22, 2024 | |
| GDRX GoodRx Holdings | Maintains: Equal-Weight | $8 → $5.5 | $2.14 | +157.01% | 9 | Nov 10, 2023 | |
| OSCR Oscar Health | Maintains: Equal-Weight | $5 → $7.5 | $14.64 | -48.77% | 6 | Aug 30, 2023 | |
| ALHC Alignment Healthcare | Maintains: Overweight | $19 → $12 | $21.31 | -43.69% | 8 | Aug 30, 2023 | |
| DGX Quest Diagnostics | Reiterates: Equal-Weight | $145 | $198.81 | -27.07% | 17 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $365 | $147.55 | +147.37% | 7 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $403 → $420 | $871.18 | -51.79% | 27 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $120 | $5.71 | +2,001.58% | 7 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $549 → $620 | $198.39 | +212.52% | 11 | Oct 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $485 → $500 | $318.23 | +57.12% | 2 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $127 → $124 | $78.79 | +57.38% | 9 | Oct 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $296 → $318 | $277.56 | +14.57% | 11 | Aug 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $70 | $215.13 | -67.46% | 17 | Jul 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $182 → $195 | $172.54 | +13.02% | 6 | Oct 21, 2020 |
Centene
Mar 4, 2026
Maintains: Equal-Weight
Price Target: $38 → $45
Current: $37.28
Upside: +20.71%
Doximity
Feb 6, 2026
Maintains: Overweight
Price Target: $65 → $49
Current: $21.86
Upside: +124.15%
UnitedHealth Group
Jan 23, 2026
Maintains: Overweight
Price Target: $411 → $409
Current: $305.98
Upside: +33.67%
Charles River Laboratories International
Nov 11, 2025
Maintains: Equal-Weight
Price Target: $170 → $185
Current: $175.07
Upside: +5.67%
Labcorp Holdings
Jul 25, 2025
Maintains: Overweight
Price Target: $283 → $306
Current: $274.72
Upside: +11.39%
LifeStance Health Group
Apr 22, 2024
Reiterates: Overweight
Price Target: $10
Current: $6.54
Upside: +52.91%
GoodRx Holdings
Nov 10, 2023
Maintains: Equal-Weight
Price Target: $8 → $5.5
Current: $2.14
Upside: +157.01%
Oscar Health
Aug 30, 2023
Maintains: Equal-Weight
Price Target: $5 → $7.5
Current: $14.64
Upside: -48.77%
Alignment Healthcare
Aug 30, 2023
Maintains: Overweight
Price Target: $19 → $12
Current: $21.31
Upside: -43.69%
Quest Diagnostics
Aug 3, 2023
Reiterates: Equal-Weight
Price Target: $145
Current: $198.81
Upside: -27.07%
Jul 14, 2023
Reiterates: Overweight
Price Target: $365
Current: $147.55
Upside: +147.37%
Jan 6, 2023
Maintains: Overweight
Price Target: $403 → $420
Current: $871.18
Upside: -51.79%
Jan 6, 2023
Maintains: Overweight
Price Target: $140 → $120
Current: $5.71
Upside: +2,001.58%
Oct 31, 2022
Maintains: Overweight
Price Target: $549 → $620
Current: $198.39
Upside: +212.52%
Oct 21, 2022
Maintains: Equal-Weight
Price Target: $485 → $500
Current: $318.23
Upside: +57.12%
Oct 11, 2022
Maintains: Overweight
Price Target: $127 → $124
Current: $78.79
Upside: +57.38%
Aug 17, 2022
Maintains: Overweight
Price Target: $296 → $318
Current: $277.56
Upside: +14.57%
Jul 14, 2022
Maintains: Overweight
Price Target: $74 → $70
Current: $215.13
Upside: -67.46%
Oct 21, 2020
Maintains: Overweight
Price Target: $182 → $195
Current: $172.54
Upside: +13.02%